Amoéba: H1 2018 bottom line impacted by restructuring expenses - all eyes on potential US approval (
Amoéba: (CORPORATE, Fair Value EUR13 (+192%))H1 2018 bottom line impacted by restructuring expenses - all eyes on potential US approval
Amoeba unveiled its H1 2018 results on Friday evening with revenue at EUR62k vs. EUR75k last year. H1 2018 net income was down yoy mainly due to the impact from restructuring expenses as announced by the company earlier this year. The group's cash position stood at EUR6.3m at end-June vs. EUR7.38m at end-April. The current cash position should enable the company to continue its activities until the end of August 2019. All eyes remain on the potential US approval with the regulatory decision date expected for Q1 2019.
Amoeba SA. Amoeba SA is a France-based company that develops, manufactures and markets biological products. The Company specializes in disruptive biological solutions for the treatment of Legionella, amoeba and biofilm in water. The Company's offering includes products and services, such as: Cleantech biological solution, a patented technological disruptive product with no impact on the environment; amoebic analyses of waters of wet cooling towers (TAR), hot sanitary waters, industrial waters and waters of swimming pools; as well as Legionella tests of industrial waste water, among others. The Company is engaged in various technical, commercial, industrial and investment partnerships.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.